-
More than 350 drugs will increase in price, including Pfizer, GSK, BMS, AZ and Sanofi
Time of Update: 2023-02-03
Recently, according to Reuters, according to healthcare research company 3 Axis Advisors According to the data analyzed, multinational big pharmaceutical companies including Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, AstraZeneca and Sanofi plan to raise 350 in the United States in early January 2023 The price of a variety of unique drugs.
-
! Novartis and GSK "interact" frequently, Pfizer 5 times to the bottom of the attempt...
Time of Update: 2022-12-30
The total amount of mergers and acquisitions exceeded $70 billion Pfizer rode the dust The capital winter also accelerates the M&A process between pharmaceutical companies.
The total amount of mergers and acquisitions exceeded $70 billion Pfizer rode the dust The capital winter also accelerates the M&A process between pharmaceutical companies.
-
"Fight" family bottom style into the Bo show! Roche AZ Pfizer GSK Sanofi collective "drying muscles
Time of Update: 2022-11-15
E drug managers continue to pay attention to the 5th year of the Expo, and clearly perceive that at the 2022 Expo, it seems that each MNC has come up with the most competitive innovation "foundation" to show to the entire industry and consolidate confidence in its future development in the Chinese market.
-
Biotech Survive Broken Tail! Stone Medicine, Zhongsheng, GSK, BMS, Pfizer throw olive branches! Is it time to dig the bottom?
Time of Update: 2022-10-25
01 Go in both directions, each take what you need Biotech joins hands with Big Pharma to survive the winter On April 1 this year, Nature Reviews Drug Discovery published a statistical article on the field of innovative drugs in China, and the content analysis pointed out that as of July 1, 2021, there were 2,251 drugs (including drugs and biological products) under development in all therapeutic areas in China, including 418 first-in-class, 473 fast-follower, and 923 me-too.
-
Top 10 most innovative pharmaceutical companies: Pfizer, AZ, GSK...
Time of Update: 2021-03-22
From the biotech companies behind the first mRNA vaccines (Pfizer BioNTech and Moderna) to real estate developers providing high-quality affordable housing (Stablegold Hospitality), the world’s 50 most innovative companies are committed to solving COVID-19 transformation Society.
-
Pfizer vaccine protects against asymptomatic infection by up to 94%; GSK/Vir-medium antibodies reduce hospitalization/death risk by 85%
Time of Update: 2021-03-21
95;overflow-wrap:break-word ;'> WuXi AppTec Content Team Mapping The largest real-world study: BNT162b2 is 94% effective in preventing asymptomatic infections Today, Pfizer (Pfizer), BioNTech and the Israeli Ministry of Health jointly announced that real world data show that the new crown vaccine BNT162b2 jointly developed by Pfizer and BioNTech not only has 97% effectiveness in preventing symptomatic COVID-19 , but also in prevention The effectiveness of asymptomatic infection also reached 94% .
-
The European Union has approved GSK's acquisition of Pfizer's consumer health business
Time of Update: 2021-02-26
The European Commission recently announced that it has approved GlaxoSmithKline's (GSK) acquisition of Pfizer's consumer health business under EU merger regulations, a decision that will depend on Pfizer's global divestiture of local pain management products under the ThermaCare brand.
-
Pfizer's GSK Sanofi Mercer East vaccine sales growth outperformed overall results
Time of Update: 2021-02-22
He cites GlaxoSmithKline's newly approved malaria vaccine, the first vaccine against malaria, as evidence that companies that remain in the pharmaceutical industry will offer innovations to both developing and developed countries.
-
GSK and Pfizer invested more than $50 million in oral integrated products
Time of Update: 2021-02-21
, a US-based start-up biotech company, recently announced the results of round A financing: multi-strategic investors bought the company's next-generation oral integrator concept for $51.5m. Notably,
-
Pfizer OUT! Johnson, Johnson and Johnson, Roche may buy GSK
Time of Update: 2020-06-03
Pharmaceuticals, June 18 (Upi) -- Rumours have been swirling over the past few weeks that GlaxoSmithKline has been a target for Pfizer, but this time Uk-based traders are targeting another potential
-
GSK will push five new drugs Novo expand smalutide Pfizer most want to improve is...
Time of Update: 2020-05-31
As soon as the J.M Morgan Health Conference opened, the chief executive of GlaxoSmithKline (GSK) held a press conference, and Alexion unveiled Ultomiris's latest plans in another hall What research an
-
GSK will launch 5 new drugs, Novo will expand the field of simalutide treatment, Pfizer's most wanted to improve is
Time of Update: 2020-01-16
Just after the opening of J.M Morgan medical health conference, CEO of GSK held a conference, and alexion released the latest plans of ultomiris in another hall Takeda, Novo Nordisk, Pfizer and other
-
GSK will launch 5 new drugs novo to expand simalutide Pfizer's most desired improvement is
Time of Update: 2020-01-15
Compiling coco J Just after the opening of the M Morgan Healthcare Conference, the CEO of GSK held a conference, and alexion announced the latest plans of ultomiris in another hall Takeda, Novo Nordis
-
GSK completes the transaction with Pfizer and establishes a new global leading joint venture of consumer health products
Time of Update: 2019-08-02
August 1, 2019 / Meitong news agency / -- on August 1, GlaxoSmithKline (LSE / NYSE: GSK) announced that it had completed the transaction with Pfizer, integrated the consumer health products business o
-
Roche, Pfizer and GSK will face the biggest patent cliff crisis? How can 2019 pharmaceutical tycoon break the situation when sales drop?
Time of Update: 2019-03-07
In 2019, many heavy-duty products from MNC are facing the huge challenge of patent cliff The challenge of generic drugs and biological similar drugs has been gradually clear, and even within the paten